Clinical Trials Logo

Clinical Trial Summary

Myositis is a disease, believed to be due to immune cells, cells which normally protect the body, but are now attacking the muscles and other organ systems within body. As a result, the affected muscles and organs fail to work properly causing weakness, difficulty swallowing, skin rash, respiratory problems, heart problems, joint stiffness, soft tissue calcification and vasculitis (blood circulation problems). The likelihood of progression of this disease is high. This study is designed to examine whether treating patients with high dose cyclophosphamide (a drug which reduces the function of the immune system) and ATG (a protein that kills the immune cells that are thought to be causing this disease), followed by return of previously collected blood stem cells will stop the progression of myositis.


Clinical Trial Description

Conditioning Regimen (In order to assure sterility testing, a minimum of 14 days will be required between stem cell collection and starting the conditioning regimen).

The conditioning regimen is outlined in below:

Cyclophosphamide 50 mg/kg/day will be given IV over 1 hour in 250 cc of normal saline on day -5, -4, -3, and -2. If actual weight is < ideal weight, cyclophosphamide will be given based on actual weight. If actual weight is > ideal weight, cyclophosphamide will be given as adjusted ideal weight. Adjusted ideal weight = ideal weight + 40% (actual weight minus ideal weight).

Mesna 50mg/kg/day will be given IV over 24 hours in 250 cc of normal saline or D5W starting at 10AM each dose. Weight base is calculated same as cyclophosphamide as above.

1ATG (rabbit) 0.5 mg/kg on day -6 and 1mg/kg on day -5, -4, -3, -2 and -1 (total 5.5mg/kg, no dose adjustment) will be given IV over 10 hours in 250 cc of normal saline beginning at least 1 hour after infusion of cyclophosphamide. Premedicate with acetaminophen 650 mg po and diphenhydramine 25 mg po/IV 30 minutes before the infusion.

Methylprednisolone- A suggested dose of 250mg IV should be administered 30 minutes before each ATG infusion.

Hydration- A suggested rate of 125 cc/hr NS should be given starting 6 hours before the first cyclophosphamide dose and continued until 24 hours after the last cyclophosphamide dose. The rate of hydration will be aggressively adjusted. BID weights will be obtained. Amount of fluid can be modified based on patient's fluid status. Minimum target urine output is 2 liters/m2/day

G-CSF 5 mcg/kg/day will be given subcutaneously and continued until the absolute neutrophil counts reaches at least 500/µl.

Rituxan 500 mg will be given IV on the day before the first dose of ATG and the day after stem cell infusion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00278564
Study type Interventional
Source Northwestern University
Contact
Status Terminated
Phase Phase 1
Start date September 2005
Completion date July 2016

See also
  Status Clinical Trial Phase
Recruiting NCT06374719 - WiTNNess - TNNT1 Myopathy Natural History Study
Not yet recruiting NCT03633565 - Comparative Study of Strategies for Management of Duchenne Myopathy (DM) Phase 4
Enrolling by invitation NCT02235220 - Reduction of Masticatory Muscle Activity by Restoring Canine Guidance N/A
Completed NCT01642056 - EPI-743 for Metabolism or Mitochondrial Disorders Phase 1/Phase 2
Completed NCT02011282 - Electro-Neuro-Muscular Stimulation in ICU N/A
Completed NCT01702987 - Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS N/A
Active, not recruiting NCT01225614 - Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Phase 3
Recruiting NCT03749538 - Acute Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies N/A
Completed NCT02442986 - Neurological Outcome in Surgical and Non-surgical Septic Patients N/A
Recruiting NCT01022450 - Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients N/A
Withdrawn NCT00990834 - Muscle Characteristics Associated With Statin Therapy N/A
Active, not recruiting NCT00937001 - Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness N/A
Recruiting NCT01353430 - Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
Completed NCT03751644 - Peripherical Neuromuscular Electrical Stimulation in Systemic Autoimmune Myopathies N/A
Completed NCT02765828 - Identification of Tongue Involvement in Late-Onset Pompe Disease
Recruiting NCT05599568 - Repeated Bout Effect i Neuromuscular Diseases N/A
Withdrawn NCT02124070 - Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis Phase 1/Phase 2
Completed NCT02706314 - Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
Recruiting NCT03042286 - SAPhIRE Statin Adverse Drug Reaction
Not yet recruiting NCT04941079 - Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients :a Prospective Observational Study